Blau Farmaceutica (BSP:BLAU3) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:BLAU3 Blau Farmaceutica SA BSP:BLAU3
83 GF Score
Price R$10.56
GF Value R$11.03
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Blau Farmaceutica Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Blau Farmaceutica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was R$244 Mil. Blau Farmaceutica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was R$609 Mil. Blau Farmaceutica's annualized EBITDA for the quarter that ended in Jun. 2026 was R$428 Mil. Blau Farmaceutica's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 1.99.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Blau Farmaceutica's Debt-to-EBITDA or its related term are showing as below:

BSP:BLAU3' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.6   Med: 1.12   Max: 1.92
Current: 1.65

During the past 12 years, the highest Debt-to-EBITDA Ratio of Blau Farmaceutica was 1.92. The lowest was 0.60. And the median was 1.12.

BSP:BLAU3's Debt-to-EBITDA is ranked worse than
50.52% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs BSP:BLAU3: 1.65

Blau Farmaceutica  (BSP:BLAU3) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Blau Farmaceutica Debt-to-EBITDA Related Terms

Blau Farmaceutica Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Blau Farmaceutica's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blau Farmaceutica Debt-to-EBITDA Chart

Blau Farmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Blau Farmaceutica Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BSP:BLAU3 vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blau Farmaceutica Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Blau Farmaceutica's Debt-to-EBITDA falls into.


BSP:BLAU3
83GF Score
Blau Farmaceutica SA BSP:BLAU3
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Blau Farmaceutica Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Blau Farmaceutica's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(285.593 + 313.541) / 527.834
=1.14

Blau Farmaceutica's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(244.461 + 608.632) / 427.916
=1.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?

Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued. The current stock price of R$10.56 is trading 4.3% below its estimated GF Value™ of R$11.03. GuruFocus considers Blau Farmaceutica to be Fairly Valued.

Key valuation signals for BSP:BLAU3:

  • Debt-to-EBITDA:
  • GF Value™: R$11.03 vs. price of R$10.56 (4.3% below fair value)
  • GF Score™: 83/100 with 8 warning signs

No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Blau Farmaceutica Business Description

Address Rodovia Raposo Tavares, No. 2833, Km 30.5, Barro Branco, Cotia, SP, BRA, 06705-030
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
83GF Score

Get the complete analysis for BSP:BLAU3

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$10.56
Price
R$11.03
GF Value